Care of the Big-Hearted: An interactive discussion of heart disease

Care of the Big-Hearted: An interactive discussion of heart disease

Hypertrophic cardiomyopathy (HCM) is the common form of hereditary disease, the director of Health's HCM Program, Care the Big-Hearted will have information about HCM and death risk assessment in dynamic, new treatment options, at 1800 East Care of the Beltline Southeast, click here. If cannot attend, call (616)-885-5355..

Kevin Bergquist remembers the day clearly. Five years ago, the dedicated husband and father, then 43, was walking to work in Ann Arbor when he suddenly felt ill. Although Bergquist made it to his destination, he was still not feeling quite like himself. Unsettled, he headed to the Michigan Medicine emergency department as a precaution. LISTEN UP: Add the new Michigan Medicine News Break to your Alexa-enabled device, or subscribe to our daily updates on iTunes, Google Play and Stitcher. There he hcm heart disease learned his instincts were right; doctors said he was experiencing atrial fibrillation (Afib), an irregular heartbeat that affects blood flow to the heart muscle and the rest of the body. Afib can cause palpitations in the chest and prevent the heart from pumping efficiently. Risk factors for this arrhythmia include advanced age, obesity, sleep apnea, heart failure, high blood pressure and heart valve disease. Other than sleep apnea, Bergquist didn’t have other significant risk factors – or so he thought.

Data Support Progression to Phase Clinical Trial Patients Obstructive Hypertrophic Cardiomyopathy to 2019 SOUTH SAN Sept. Cytokinetics Announces Data 16, Incorporated CYTK) today announced data Phase 1 CK-3773274 (CK-274) were presented poster session at HFSA 23rd Annual Scientific Philadelphia. Irregular Heartbeat Unmasks The met its primary objectives to assess tolerability single multiple oral doses as well as to PK/PD relationship to cardiac function. data support advancement CK-274 into Phase clinical trial patients obstructive hypertrophic cardiomyopathy which expected to begin 2019. CK-274 novel selective cardiac myosin development for treatment hypertrophic cardiomyopathy.

Comments

Popular posts from this blog

Here's everything you need to know about the weight-loss Optavia Diet

US military families face challenges getting healthcare for kids

Dog About Town: Celebrate a new howl-iday with your pooch